Suji Uhm, MD
Obstetrics/Gynecology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · University of Pittsburgh Physicians
Looking this up.
Hospitals listed: Magee Womens Hospital of Upmc Health System. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Uhm’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A154345 · Current
Licensed to practise in California · since 2018 · expires 2027-07-31 · Case Western Reserve University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Magee Womens Hospital of Upmc Health SystemPittsburgh, PAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of UPMC, which runs 34 hospitals in 3 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.464, Oct 2024 – Sep 2025
See every measure and the patient survey for Magee Womens Hospital of Upmc Health System
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 8 the same, 0 worse of 8 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.464 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 437 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.21 (0.79 to 1.63) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.15 (110.62 to 233.69) · 25 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 33 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 859 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,432 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,498 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.85 (1.55 to 6.16) · 569 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.03 (0.34 to 3.71) · 378 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.62 (1 to 4.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.49 (0.02 to 16.96) · 392 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (1.99 to 9.93) · 362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.18) · 158 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.28 (0.24 to 2.33) · 1,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 274 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.246 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.593 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.525 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.145 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.39 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 43 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -42.1 · 34 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 134 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.9 to 5.5) · 2,366 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (10.5 to 13.1) · 2,366 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 229 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.1 to 16.1) · 736 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 585 cases | No different | Jan 2024 – Dec 2024 |
What patients said (368 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Medicaid work
$1,020 in 2024
Medicaid paid $1,020 for 27 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 27 | $1,020 |
| 2024 | 27 | 1 | 15 | $1,020 |
| 2023 | 900 | 14 | 77 | $28,231 |
| 2022 | 1,897 | 27 | 98 | $50,208 |
| 2021 | 179 | 7 | 43 | $5,477 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 321 | $12,952 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 144 | $3,681 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 142 | $3,502 |
| Nursing assessment / evaluation | 15 | $3,258 |
| Long return visit (40+ min) | 12 | $1,342 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 37 | $791 |
| URINE PREGNANCY TEST | 104 | $578 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 12 | $504 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 12 | $386 |
| Antibody; HIV-2 | 25 | $363 |
| Antibody; HIV-1 | 25 | $318 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 | 25 | $275 |
2022
| Clinic visit/encounter, all-inclusive | 451 | $19,112 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 239 | $6,092 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 238 | $5,909 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 145 | $5,125 |
| Long return visit (40+ min) | 37 | $3,358 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 72 | $1,063 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 29 | $850 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 16 | $846 |
| URINE PREGNANCY TEST | 164 | $811 |
| Antibody; HIV-2 | 46 | $666 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation | 17 | $649 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 15 | $644 |
2021
| Clinic visit/encounter, all-inclusive | 67 | $2,591 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 18 | $793 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 24 | $671 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 24 | $646 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 14 | $452 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 19 | $265 |
| URINE PREGNANCY TEST | 13 | $59 |
Money from drug and device companies
$1,375 in 2024
| 2024 | 1 | 1 | $1,375 | $1,375 |
| 2023 | 1 | 3 | $2,406 | $2,531 |
| 2022 | 1 | 6 | $4,125 | $4,294 |
| 2021 | 1 | 1 | None | $74 |
| 2019 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Organon | Nexplanon | $1,375 | 1 payment
|
See the published payment
| Organon | Paid to speak or teach · 2024-10-30 | Nexplanon | $1,375 |
See earlier years (2023, 2022, 2021, 2019)
2023: $2,531
| Organon | Nexplanon | $2,531 | 3 payments
|
2022: $4,294
| Organon | Nexplanon | $4,294 | 6 payments
|
2021: $74
| Organon | Nexplanon | $74 | 1 payment
|
2019: $125
| Mayne Pharma | Doryx | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Organon LLC · Efficacy and Safety of Nexplanon 36 To 60 Months Post Insertion · 2023 | Their institution | $96,921 |
| Organon LLC · A Study To Assess Contraceptive Efficacy and Safety of Etonogestrel (Eng) Implant Beyond 3 Years of Use (Mk-8415-060) · 2022 | Their institution | $70,999 |
| Organon LLC · 2024 | Their institution | $38,622 |
| Organon LLC · 8415-8415-060-Pn060-Extended Duration Study (Celanese + 2 Years)-Contraception-Sc-Imp-Supplemental Registration-USA-Ld-B · 2021 | Their institution | $31,347 |
| Organon LLC · A Phase 3, Open-Label, Multi-Center, Single Arm Study To Assess Contraceptive Efficacy and Safety of the Etonogestrel Mk-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age Or Younger · 2021 | Their institution | $25,991 |
| Organon LLC · 2022 | Their institution | $20,890 |
| Merck Sharp & Dohme Corporation · A Phase 3, Open-Label, Multi-Center, Single Arm Study To Assess Contraceptive Efficacy and Safety of the Etonogestrel Mk-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age Or Younger · 2021 | Their institution | $20,831 |
| Organon Llc · 2025 | Their institution | $2,500 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 77.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1992123103
- Licence
- CA A154345California A154345: Current · expires 2027-07-31
- Group
- Stanford Health Care · University of Pittsburgh Physicians
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VC0300X (207VC0300X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-04-03
- NPI last updated
- 2025-12-01
- NPI record certified
- 2025-12-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Halket St, Pittsburgh, PA, 15213
This office lists an electronic records connection.